This section will focus on the potential diagnostic value of TRIM21 and its autoantibodies in the development of CTD-ILD based on currently published clinical research data and preclinical studies, as well as the possible molecular mechanisms involved in the pathogenic process. Here, TRIM21 is linked to interstitial lung disease.